Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Medivir AB ( (SE:MVIR) ) has shared an update.
Medivir has announced the enrollment of the first patient in the FLEX-HCC study, a randomized phase 2 trial in Korea comparing its liver-targeted chemotherapy fostrox plus lenvatinib against lenvatinib alone in second-line advanced hepatocellular carcinoma. Led by the Korean Cancer Study Group across 12 major hospitals, the study aims to demonstrate superior efficacy of the combination therapy, with response rate and survival outcomes carefully tracked.
The launch of FLEX-HCC marks a key milestone in advancing fostrox toward becoming a new treatment option in advanced liver cancer, an area with persistent high mortality and limited benefit from current targeted therapies. Positive results could strengthen Medivir’s position in oncology, support the blockbuster potential of fostrox, and provide a clinically meaningful alternative for patients who currently face poor prognoses and few effective second-line options.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a Stockholm-listed pharmaceutical company focused on developing innovative therapies for diseases with high unmet medical need. Its lead programs include fostrox, a precision chemotherapy designed to selectively target liver cancer cells, and MIV-711 for Osteogenesis Imperfecta, both viewed as having significant commercial potential in underserved markets.
Average Trading Volume: 7,562,957
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.07B
For a thorough assessment of MVIR stock, go to TipRanks’ Stock Analysis page.